Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0058 | 0.4934 | 0.4934 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0058 | 0.4934 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0018 | 0.034 | 0.034 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0018 | 0.034 | 0.034 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase | 0.0058 | 0.4934 | 0.4934 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0.034 | 0.069 |
Toxoplasma gondii | exonuclease III APE | 0.0018 | 0.034 | 0.034 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0102 | 1 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0102 | 1 | 1 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase | 0.0058 | 0.4934 | 0.4934 |
Plasmodium falciparum | glutathione reductase | 0.0058 | 0.4934 | 0.4934 |
Leishmania major | 2-oxoglutarate dehydrogenase, e3 component, lipoamidedehydrogenase-like protein | 0.0058 | 0.4934 | 0.4934 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0102 | 1 | 1 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0058 | 0.4934 | 1 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0018 | 0.034 | 0.034 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0018 | 0.034 | 0.034 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0018 | 0.034 | 0.034 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0018 | 0.034 | 0.069 |
Toxoplasma gondii | pyruvate dehydrogenase complex subunit PDH-E3II | 0.0058 | 0.4934 | 0.4934 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0058 | 0.4934 | 1 |
Trypanosoma brucei | dihydrolipoyl dehydrogenase | 0.0058 | 0.4934 | 0.4934 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0018 | 0.034 | 0.069 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0058 | 0.4934 | 1 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase, point mutation | 0.0058 | 0.4934 | 0.4934 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0018 | 0.034 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0058 | 0.4934 | 1 |
Toxoplasma gondii | NADPH-glutathione reductase | 0.0058 | 0.4934 | 0.4934 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0058 | 0.4934 | 0.4934 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0102 | 1 | 1 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Toxoplasma gondii | thioredoxin reductase | 0.0102 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0018 | 0.034 | 0.034 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0058 | 0.4934 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0102 | 1 | 1 |
Treponema pallidum | NADH oxidase | 0.0058 | 0.4934 | 1 |
Plasmodium falciparum | dihydrolipoyl dehydrogenase, mitochondrial | 0.0058 | 0.4934 | 0.4934 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0058 | 0.4934 | 1 |
Mycobacterium tuberculosis | Probable soluble pyridine nucleotide transhydrogenase SthA (STH) (NAD(P)(+) transhydrogenase [B-specific]) (nicotinamide nucleot | 0.0058 | 0.4934 | 0.4934 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0.034 | 0.034 |
Trypanosoma brucei | trypanothione reductase | 0.0102 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0058 | 0.4934 | 1 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0102 | 1 | 1 |
Leishmania major | trypanothione reductase | 0.0102 | 1 | 1 |
Plasmodium falciparum | dihydrolipoyl dehydrogenase, apicoplast | 0.0058 | 0.4934 | 0.4934 |
Schistosoma mansoni | dihydrolipoamide dehydrogenase | 0.0058 | 0.4934 | 0.4934 |
Leishmania major | acetoin dehydrogenase e3 component-like protein | 0.0058 | 0.4934 | 0.4934 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0018 | 0.034 | 0.034 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0058 | 0.4934 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0018 | 0.034 | 0.034 |
Echinococcus granulosus | dihydrolipoamide dehydrogenase | 0.0058 | 0.4934 | 0.4934 |
Echinococcus multilocularis | dihydrolipoamide dehydrogenase | 0.0058 | 0.4934 | 0.4934 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0018 | 0.034 | 0.069 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0058 | 0.4934 | 0.4934 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0058 | 0.4934 | 0.4934 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0102 | 1 | 1 |
Plasmodium vivax | dihydrolipoyl dehydrogenase, apicoplast, putative | 0.0058 | 0.4934 | 0.4934 |
Plasmodium falciparum | thioredoxin reductase | 0.0058 | 0.4934 | 0.4934 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Brugia malayi | Thioredoxin reductase | 0.0102 | 1 | 1 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0058 | 0.4934 | 1 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Brugia malayi | Pyridine nucleotide-disulphide oxidoreductase, dimerisation domain containing protein | 0.0043 | 0.3151 | 0.3151 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0018 | 0.034 | 0.034 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0.034 | 0.034 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Plasmodium falciparum | glutathione reductase | 0.0102 | 1 | 1 |
Plasmodium vivax | dihydrolipoyl dehydrogenase, mitochondrial, putative | 0.0058 | 0.4934 | 0.4934 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0058 | 0.4934 | 0.4934 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0.034 | 0.069 |
Schistosoma mansoni | ap endonuclease | 0.0018 | 0.034 | 0.034 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0018 | 0.034 | 0.069 |
Plasmodium vivax | glutathione reductase, putative | 0.0102 | 1 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0102 | 1 | 1 |
Trypanosoma cruzi | dihydrolipoyl dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Brugia malayi | alpha keto acid dehydrogenase complex, E3 component, lipoamide dehydrogenase | 0.0043 | 0.3151 | 0.3151 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0018 | 0.034 | 0.034 |
Trypanosoma cruzi | dihydrolipoyl dehydrogenase, putative | 0.0058 | 0.4934 | 0.4934 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Log MIC (functional) | = 1.66 | Antibacterial activity against pathogenic strains (both Gram-positive, Gram-negative bacteria) and expressed as log MIC (log Minimum Inhibitory Concentration) | ChEMBL. | 8496912 |
MIC (functional) | > 128 ug ml-1 | Minimum inhibitory concentration against Pseudomonas species. | ChEMBL. | 8496912 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.